Gastroenterology

Back to articles

Concomitant use of PPIs, clopidogrel not associated with increased cardiovascular events

KEY POINT

No increased risk of cardiovascular (CV) events was observed in patients with myocardial infarction (MI) who received proton pump inhibitors (PPIs) and clopidogrel (Plavix—Bristol-Myers Squibb/sanofi aventis) regardless of whether they carried cytochrome P450 (CYP)2C19 variants, which have been linked to a reduction in clopidogrel’s effectiveness.